HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

NVP ADW742

an IGF-I receptor kinase inhibitor

Also Known As:

NVP-ADW742

Networked: 7 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Pyrroles: 369
      - NVP ADW742: 7
  - Pyrimidines: 510
    - NVP ADW742: 7

Experts

1.	García-Echeverría, Carlos: 3 articles (02/2005 - 03/2004)
2.	Hofmann, Francesco: 3 articles (02/2005 - 03/2004)
3.	Yang, Lin: 2 articles (06/2011 - 01/2010)
4.	Buchdunger, Elisabeth: 2 articles (02/2005 - 05/2004)
5.	Krystal, Geoffrey W: 2 articles (02/2005 - 05/2004)
6.	Litz, Julie: 2 articles (02/2005 - 05/2004)
7.	Warshamana-Greene, G Sakuntala: 2 articles (02/2005 - 05/2004)
8.	Chen, Xiaoman: 1 article (01/2021)
9.	Feng, Jingjing: 1 article (01/2021)
10.	Xu, Shan: 1 article (01/2021)

Related Diseases

1.	Lung Neoplasms (Lung Cancer) 01/01/2015 - "The purpose of this study was to investigate the prognostic role of IGF-1R expression in surgically resected non-small-cell lung cancer (NSCLC), and responses to IGF-1R tyrosine kinase inhibitor NVP-ADW742 in a panel of lung cancer cell lines. "
2.	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/01/2015 - "The purpose of this study was to investigate the prognostic role of IGF-1R expression in surgically resected non-small-cell lung cancer (NSCLC), and responses to IGF-1R tyrosine kinase inhibitor NVP-ADW742 in a panel of lung cancer cell lines. "
3.	Neoplasms (Cancer) 01/01/2021 - "NVP-ADW742 efficiently increases cancer cell response to radiation. " 06/01/2011 - "NVP-ADW742 enhanced the chemosensitivity of Daoy to temozolomide in vitro, as a potent anti-tumor agent highly selective against IGF-IR." 03/01/2004 - "NVP-ADW742 monotherapy or its combination with cytotoxic chemotherapy had significant antitumor activity in an orthotopic xenograft MM model, providing in vivo proof of principle for therapeutic use of selective IGF-1R inhibitors in cancer." 06/01/2011 - "The novel IGF-I receptor (IGF-IR) kinase inhibitor NVP-ADW742 has in vitro activity against tumors. " 03/01/2004 - "Specific IGF-1R inhibition with neutralizing antibody, antagonistic peptide, or the selective kinase inhibitor NVP-ADW742 has in vitro activity against diverse tumor cell types (particularly multiple myeloma), even those resistant to conventional therapies, and triggers pleiotropic antiproliferative/proapoptotic molecular sequelae, delineated by global transcriptional and proteomic profiling. "
4.	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 02/15/2005 - "The insulin-like growth factor-I receptor kinase inhibitor, NVP-ADW742, sensitizes small cell lung cancer cell lines to the effects of chemotherapy." 05/01/2004 - "The insulin-like growth factor-I (IGF-I) receptor kinase inhibitor NVP-ADW742, in combination with STI571, delineates a spectrum of dependence of small cell lung cancer on IGF-I and stem cell factor signaling."
5.	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/01/2010 - "The insulin-like growth factor-1 receptor kinase inhibitor, NVP-ADW742, suppresses survival and resistance to chemotherapy in acute myeloid leukemia cells."

Related Drugs and Biologics

1.	Tyrosine Kinase Inhibitors
2.	Phosphotransferases (Kinase)
3.	IGF Type 1 Receptor (IGF 1 Receptor)
4.	Neutralizing Antibodies
5.	Therapeutic Uses
6.	Stem Cell Factor
7.	Peptides (Polypeptides)
8.	Insulin-Like Growth Factor I (IGF-1)
9.	Insulin (Novolin)
10.	Temozolomide (Temodar)

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Therapeutics